fashion -WSS

fashion

author：fashion 2025-09-30 00:45:43 - browse：2

Scientist walks up a strand of DNA -- First Opinion coverage from STAT — Adobe

Eli Lilly said Tuesday that it will pay $200 million to gene-editing firm Beam Therapeutics for Beam’s stake in Verve Therapeutics, another gene-editing company focused on treatments for heart disease.

The deal, which also includes future milestone payments, is evidence that despite the pressure on biotechnology stocks there is still interest in very early cutting-edge technologies among big pharmaceutical players. It also provides Beam, which announced on Oct. 19 that it would cut 100 jobs, or 20% of its workforce, to save cash, a large infusion of money.

“This is like a true win-win-win deal, which is rare in this business, but it’s really, really exciting to see,” said John Evans, Beam’s CEO, in an interview with STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： The new shift in health care is toward less care

WSS

Will General Catalyst be the first of many hospital takeovers?

PBM reforms clear House panel

In key trial, Verve's treatment lowers cholesterol levels in patients

Hospitals look to new technology to keep health care workers safe

NYU radiologists take on the challenge of expensive MRI machines

Ransomware attacks on hospitals: Study outlines patient impact

hotspot

fashion

hotspot

Peter Hotez and the public health issue of online harassment

FDA approves Recor Medical high blood pressure device

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Childhood cancer progress stalls for Black, Hispanic kids: Report

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

A daunting task: navigating dual Medicare, Medicaid eligibility

ChatGPT in medicine: STAT answers readers' burning questions

Ransomware attacks on hospitals: Study outlines patient impact

After affirmative action ruling, medical educators look to 'holistic review'

Childhood cancer progress stalls for Black, Hispanic kids: Report

knowledge

Diversify hospital leadership teams to protect BIPOC patient health

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Diversify hospital leadership teams to protect BIPOC patient health

Medicare solvency divides Republicans at the presidential debate

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Astellas still sees hope in its gene therapy after four deaths

hotspot

explore

explore

focus